Novotech
Date | Investors | Amount | Round |
---|---|---|---|
* | N/A | Secondary | |
* | N/A | Acquisition | |
* | N/A Valuation: $2.3b | Secondary | |
* | N/A | $505m | Debt |
* | N/A | $255m Valuation: $3.0b | Growth Equity non VC |
Total Funding | - |
Recent News about Novotech
EditNovotech CRO is a leading Contract Research Organization (CRO) specializing in providing comprehensive clinical research solutions worldwide. The company serves a diverse range of clients, including pharmaceutical, biotechnology, and medical device companies, primarily focusing on the Asia-Pacific region. Novotech operates in a highly competitive market, leveraging its extensive network of offices across key locations such as Australia, New Zealand, China, India, South Korea, and Southeast Asia to offer localized expertise and efficient regulatory navigation.
The business model of Novotech revolves around offering end-to-end clinical trial services, from initial study design and regulatory submissions to patient recruitment, data management, and final reporting. This full-service approach ensures that clients can conduct their clinical trials seamlessly, reducing time-to-market for new therapies and medical devices. Novotech generates revenue through service contracts with its clients, often structured as multi-year agreements that provide a steady stream of income.
Novotech's competitive edge lies in its deep understanding of the regulatory landscapes across the Asia-Pacific region, its robust operational infrastructure, and its commitment to quality and compliance. The company also emphasizes the use of real-world evidence and advanced data analytics to accelerate clinical trials, thereby enhancing the efficiency and effectiveness of the research process.
Keywords: Clinical Research, CRO, Asia-Pacific, Pharmaceutical, Biotechnology, Medical Devices, Regulatory Expertise, Patient Recruitment, Data Management, Real-World Evidence.